• 1. Analysis of 1H and 13C nuclear magnetic resonance spectra of spathulenol by two-dimensional methods
  Fuyihiko Inagaki,Akira Abe J. Chem. Soc. Perkin Trans. 2 1985 1773
• 2. Non-targeted metabolomic analysis of variation of volatile fractions of ginseng from different habitats by HS-SPME-GC-MS coupled with chemometrics
  Wen-Ting Gu,Lin-Yuan Li,Wen-Jing Rui,Zhong-Wen Diao,Guo-Dong Zhuang,Xiao-Mei Chen,Zheng-Ming Qian,Shu-Mei Wang,Dan Tang,Hong-Yan Ma Anal. Methods 2022 14 3583
• 3. Biological activity of natural sesquiterpenoids containing a gem-dimethylcyclopropane unit
  María Jesús Durán-Pe?a,José Manuel Botubol Ares,James R. Hanson,Isidro G. Collado,Rosario Hernández-Galán Nat. Prod. Rep. 2015 32 1236
• 4. Protective mechanisms of Zanthoxylum bungeanum essential oil on DSS-induced ulcerative colitis in mice based on a colonic mucosal transcriptomic approach
  Huan Zhang,Zhiqing Guo,Xiao Wang,Jing Xian,Liang Zou,Chuan Zheng,Jinming Zhang Food Funct. 2022 13 9324
• 5. Supercritical CO2 extraction of Marrubium vulgare: intensification of marrubiin
  Aleksandra Gavari?,Senka Vidovi?,Krunoslav Aladi?,Stela Joki?,Jelena Vladi? RSC Adv. 2021 11 9067

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids 5,10-cycloaromadendrane sesquiterpenoids
• Sesquiterpenoids

Professional Introduction to Spathulenol (CAS No: 6750-60-3)

Spathulenol, a naturally occurring sesquiterpene lactone, is a compound with the chemical formula C??H??O? and a CAS number of 6750-60-3. This compound has garnered significant attention in the field of pharmaceutical research due to its diverse biological activities and potential therapeutic applications. Spathulenol is primarily derived from plants belonging to the family Asteraceae, particularly from species such as Senecio and Helichrysum. Its unique chemical structure, characterized by a γ-lactone ring and multiple substituents, contributes to its remarkable pharmacological properties.

The chemical structure of Spathulenol consists of a cyclopentane ring fused with a trans-decalin system, which is further modified by various functional groups. The presence of a γ-lactone moiety at the C-11 position and hydroxyl groups at specific positions enhances its interaction with biological targets. This structural complexity has made Spathulenol a subject of extensive interest in medicinal chemistry, particularly for its potential as an anti-inflammatory, antioxidant, and anticancer agent.

Recent research has highlighted the anti-inflammatory properties of Spathulenol, demonstrating its ability to modulate key inflammatory pathways. Studies have shown that Spathulenol can inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). These effects are attributed to its ability to suppress the activation of nuclear factor kappa B (NF-κB), a critical transcription factor involved in inflammatory responses. The mechanism by which Spathulenol exerts these effects involves the inhibition of IkB kinase (IKK) phosphorylation, thereby preventing the degradation of IkB and subsequent NF-κB activation.

In addition to its anti-inflammatory properties, Spathulenol has shown significant antioxidant activity. Oxidative stress is recognized as a key factor in the pathogenesis of various diseases, including neurodegenerative disorders and cardiovascular diseases. Studies have demonstrated that Spathulenol can scavenge reactive oxygen species (ROS) and reduce oxidative damage by inhibiting enzymes such as lipoxygenase and cyclooxygenase. Furthermore, Spathulenol has been shown to protect against oxidative stress-induced cell death in neuronal cells, suggesting its potential utility in neuroprotective therapies.

The anticancer potential of Spathulenol has also been extensively investigated. Preclinical studies have revealed that Spathulenol can induce apoptosis in various cancer cell lines, including breast cancer, prostate cancer, and colorectal cancer. The mechanism behind this effect involves the activation of caspase-dependent and caspase-independent pathways. Spathulenol has been shown to increase the expression of pro-apoptotic proteins such as Bax and Bid while downregulating anti-apoptotic proteins like Bcl-2 and Bcl-xL. Additionally, Spathulenol can inhibit the PI3K/Akt signaling pathway, which is frequently dysregulated in cancer cells.

Recent advancements in drug delivery systems have further enhanced the therapeutic potential of Spathulenol. Nanoparticle-based delivery systems have been developed to improve the solubility and bioavailability of this compound. These formulations have shown promising results in preclinical studies, demonstrating enhanced targeting and reduced toxicity compared to conventional formulations. The use of liposomes and polymeric nanoparticles has been particularly effective in delivering Spathulenol to tumor sites while minimizing off-target effects.

The pharmacokinetic profile of Spathulenol is another area of interest. Studies have shown that oral administration of Spathulenol results in moderate bioavailability due to its poor solubility in water. However, formulations such as self-nanoemulsifying drug delivery systems (SNEDDS) have been developed to enhance its absorption and distribution throughout the body. These formulations improve solubility and enhance permeability, leading to more effective therapeutic outcomes.

The safety profile of Spathulenol has also been evaluated through toxicological studies. Acute toxicity studies have demonstrated that Spathulenol exhibits low systemic toxicity at high doses, suggesting its potential for safe clinical use. Chronic toxicity studies are ongoing but preliminary results indicate that long-term exposure to Spathulenol does not lead to significant organ damage or adverse effects.

The future directions for research on Spathоленол include further exploration of its mechanisms of action and identification of novel therapeutic applications. Combination therapies involving Spathоленол with other chemotherapeutic agents are being investigated to enhance efficacy while reducing side effects. Additionally, preclinical studies are underway to evaluate its potential in treating neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In conclusion, Spathоленол (CAS No: 6750-60-3) is a promising natural product with diverse biological activities ranging from anti-inflammatory and antioxidant effects to anticancer properties. Its unique chemical structure contributes to its remarkable pharmacological properties, making it an attractive candidate for further pharmaceutical development. With ongoing research focused on improving its delivery systems and exploring new therapeutic applications, Spathоленол holds significant promise for future medical treatments.

• 81362-26-7(24-Methylene-3β,12β,20-dammaranetriol)
• 132970-76-4((1R,2S,3aR,4R,5S,7aR)-3a,4,5-trimethyl-1-(prop-1-en-2-yl)octahydro-1H-indene-2,5-diol)
• 121894-65-3(9,19-Cyclolanost-20-en-3-ol,24-methyl-, (3b,24R)-(9CI))
• 17020-27-8(9,19-Cyclolanostane-3,26-diol, 24-methylene-, (3b)-)
• 791835-58-0(Spiro[4.5]decan-6-ol,6,10-dimethyl-2-(1-methylethenyl)-, (2R,5R,6S,10S)-)
• 72203-24-8(1H-Cycloprop[e]azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-)
• 152340-11-9(Dicyclopenta[a,d]cyclooctene-3-methanol,tetradecahydro-9-hydroxy-a,a,9,10a-tetramethyl-6-methylene-,(3R,3aS,6aR,9S,9aS,10aR)-rel-(-)- (9CI))
• 103629-94-3(9,19-Cycloergost-24(28)-ene-3,6-diol,14-methyl-, (3b,5a,6a)- (9CI))
• 117193-18-7(9,19-Cycloergost-20-en-3-ol,4,14-dimethyl-, (3b,4a,5a,24R)- (9CI))
• 152340-12-0(Dicyclopenta[a,d]cyclooctene-3-methanol,tetradecahydro-6-hydroxy-a,a,6,10a-tetramethyl-9-methylene-,(3R,3aS,6S,6aR,9aS,10aR)-rel-(+)- (9CI))